FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014372335> ?p ?o ?g. }

• W2014372335 endingPage "557" @default.
• W2014372335 startingPage "548" @default.
• W2014372335 abstract "What is already known about this subject • Nelfinavir is an HIV protease inhibitor, substrate of the transporter P‐glycoprotein and metabolized via CYP2C19, CYP3A4 and CYP3A5 enzymes. • Pharmacokinetic studies have shown wide interindividual variability of nelfinavir concentrations, some of this variability perhaps caused by variant drug metabolism or transporter genes. • For CYP3A4*1B and CYP3A5*3 polymorphism, results from three studies are in agreement, showing no difference in nelfinavir concentrations between patients with these different genotypes. • However, for MDR1 and CYP2C19 polymorphism, there have been contradictory studies, showing either no impact on nelfinavir concentration or modified concentrations which could influence virological response. What this study adds • Patients with an *1/*2 or *2/*2 genotype for CYP2C19 had a nelfinavir to M8 biotransformation divided by 2 compared with *1/*1 patients. • No evidence of any influence of MDR1 polymorphism on nelfinavir absorption could be detected. Aims To evaluate the effect of CYP2C19 polymorphism on nelfinavir and M8 pharmacokinetic variability in human immunodeficiency virus‐infected patients and to study the link between pharmacokinetic exposure and short‐term efficacy and toxicity. Methods Nelfinavir ( n = 120) and M8 ( n = 119) concentrations were measured in 34 protease inhibitor‐naïve patients. Two weeks after initiating the treatment, blood samples were taken before, 1, 3 and 6 h after drug administration. Genotyping for CYP3A4, 3A5, 2C19 and MDR1 was performed. A population pharmacokinetic model was developed to describe nelfinavir‐M8 concentration time‐courses and to estimate interpatient variability. The influence of individual characteristics and genotypes were tested using a likelihood ratio test. Estimated mean ( C mean ), maximal ( C max ) and trough ( C trough ) nelfinavir and M8 concentrations were correlated to short‐term virological efficacy and tolerance using Spearman nonparametric correlation tests. Results A one‐compartment model with first‐order absorption, elimination and metabolism to M8 best described nelfinavir data. M8 was modelled by an additional compartment. Mean pharmacokinetic estimates and the corresponding intersubject variabilities were: absorption rate 0.17 h −1 (99%), absorption lag time 0.82 h, apparent nelfinavir total clearance 52 l h −1 (49%), apparent nelfinavir volume of distribution 191 l, M8 elimination rate constant 1.76 h −1 and nelfinavir to M8 0.39 h −1 (59%) in *1/*1 patients and 0.20 h −1 in *1/*2 or *2/*2 patients for CYP2C19*2. Nelfinavir C mean was positively correlated to glycaemia and triglyceride increases ( P = 0.02 and P = 0.04, respectively). Conclusions The rate of metabolism of nelfinavir to M8 was reduced by 50% in patients with *1/*2 or *2/*2 genotype for CYP2C19 compared with those with *1/*1 genotype." @default.
• W2014372335 created "2016-06-24" @default.
• W2014372335 creator A5000406284 @default.
• W2014372335 creator A5007566056 @default.
• W2014372335 creator A5016638923 @default.
• W2014372335 creator A5032223222 @default.
• W2014372335 creator A5037696502 @default.
• W2014372335 creator A5053580384 @default.
• W2014372335 creator A5077853084 @default.
• W2014372335 date "2007-10-08" @default.
• W2014372335 modified "2023-10-17" @default.
• W2014372335 title "Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients" @default.
• W2014372335 cites W1994027559 @default.
• W2014372335 cites W2017868468 @default.
• W2014372335 cites W2025351576 @default.
• W2014372335 cites W2056794013 @default.
• W2014372335 cites W2064458956 @default.
• W2014372335 cites W2066919313 @default.
• W2014372335 cites W2079485551 @default.
• W2014372335 cites W2098938825 @default.
• W2014372335 cites W2104808569 @default.
• W2014372335 cites W2106684789 @default.
• W2014372335 cites W2110293841 @default.
• W2014372335 cites W2114549408 @default.
• W2014372335 cites W2118379411 @default.
• W2014372335 cites W2131403498 @default.
• W2014372335 cites W2136385005 @default.
• W2014372335 cites W2155608888 @default.
• W2014372335 cites W2157533742 @default.
• W2014372335 cites W2318289184 @default.
• W2014372335 cites W2330486015 @default.
• W2014372335 cites W2339219218 @default.
• W2014372335 cites W2358501499 @default.
• W2014372335 cites W4229880569 @default.
• W2014372335 doi "https://doi.org/10.1111/j.1365-2125.2007.03039.x" @default.
• W2014372335 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2291390" @default.
• W2014372335 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17922881" @default.
• W2014372335 hasPublicationYear "2007" @default.
• W2014372335 type Work @default.
• W2014372335 sameAs 2014372335 @default.
• W2014372335 citedByCount "22" @default.
• W2014372335 countsByYear W20143723352012 @default.
• W2014372335 countsByYear W20143723352013 @default.
• W2014372335 countsByYear W20143723352015 @default.
• W2014372335 countsByYear W20143723352018 @default.
• W2014372335 countsByYear W20143723352019 @default.
• W2014372335 countsByYear W20143723352021 @default.
• W2014372335 crossrefType "journal-article" @default.
• W2014372335 hasAuthorship W2014372335A5000406284 @default.
• W2014372335 hasAuthorship W2014372335A5007566056 @default.
• W2014372335 hasAuthorship W2014372335A5016638923 @default.
• W2014372335 hasAuthorship W2014372335A5032223222 @default.
• W2014372335 hasAuthorship W2014372335A5037696502 @default.
• W2014372335 hasAuthorship W2014372335A5053580384 @default.
• W2014372335 hasAuthorship W2014372335A5077853084 @default.
• W2014372335 hasBestOaLocation W20143723351 @default.
• W2014372335 hasConcept C104317684 @default.
• W2014372335 hasConcept C109650736 @default.
• W2014372335 hasConcept C112705442 @default.
• W2014372335 hasConcept C126322002 @default.
• W2014372335 hasConcept C135763542 @default.
• W2014372335 hasConcept C140840227 @default.
• W2014372335 hasConcept C142462285 @default.
• W2014372335 hasConcept C159047783 @default.
• W2014372335 hasConcept C2781160516 @default.
• W2014372335 hasConcept C2908647359 @default.
• W2014372335 hasConcept C2993143319 @default.
• W2014372335 hasConcept C3013748606 @default.
• W2014372335 hasConcept C526171541 @default.
• W2014372335 hasConcept C55493867 @default.
• W2014372335 hasConcept C55775858 @default.
• W2014372335 hasConcept C62231903 @default.
• W2014372335 hasConcept C71924100 @default.
• W2014372335 hasConcept C86803240 @default.
• W2014372335 hasConcept C98274493 @default.
• W2014372335 hasConcept C99454951 @default.
• W2014372335 hasConceptScore W2014372335C104317684 @default.
• W2014372335 hasConceptScore W2014372335C109650736 @default.
• W2014372335 hasConceptScore W2014372335C112705442 @default.
• W2014372335 hasConceptScore W2014372335C126322002 @default.
• W2014372335 hasConceptScore W2014372335C135763542 @default.
• W2014372335 hasConceptScore W2014372335C140840227 @default.
• W2014372335 hasConceptScore W2014372335C142462285 @default.
• W2014372335 hasConceptScore W2014372335C159047783 @default.
• W2014372335 hasConceptScore W2014372335C2781160516 @default.
• W2014372335 hasConceptScore W2014372335C2908647359 @default.
• W2014372335 hasConceptScore W2014372335C2993143319 @default.
• W2014372335 hasConceptScore W2014372335C3013748606 @default.
• W2014372335 hasConceptScore W2014372335C526171541 @default.
• W2014372335 hasConceptScore W2014372335C55493867 @default.
• W2014372335 hasConceptScore W2014372335C55775858 @default.
• W2014372335 hasConceptScore W2014372335C62231903 @default.
• W2014372335 hasConceptScore W2014372335C71924100 @default.
• W2014372335 hasConceptScore W2014372335C86803240 @default.
• W2014372335 hasConceptScore W2014372335C98274493 @default.
• W2014372335 hasConceptScore W2014372335C99454951 @default.
• W2014372335 hasIssue "4" @default.
• W2014372335 hasLocation W20143723351 @default.

• next